AI filing briefs · archive

8-K filings in March 2026, explained

815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 815 briefs match

newest first · times in ET

ROIVRoivant Sciences Ltd. Mar 3, 4:15 PM ET

Roivant unit settles LNP patent suit with Moderna for $2.25 billion; buyback raised to $1 billion

Positive legal/regulatory Written later 1.01 7.01 8.01

Genevant and Arbutus, both tied to Roivant, agreed to settle their patent infringement litigation against Moderna over LNP technology in its COVID-19 vaccines. Moderna will pay $950 million by July 8, 2026, plus a contingent $1.3 billion tied to a Federal Circuit appeal on 28 U.S.C. §1498. Roivant's board also raised its share repurchase authorization to $1.0 billion, including the previously approved $500 million.

Moderna to pay a noncontingent $950 million lump sum on or before July 8, 2026
Additional $1.3 billion contingent payment depends on the Federal Circuit's §1498 ruling; a partial outcome yields a prorated amount
Board increased the share repurchase program to up to $1.0 billion, funded with cash on hand, with no expiration date

Read the filing on SEC.gov ↗

CENXCENTURY ALUMINUM CO Mar 3, 4:05 PM ET

Century Aluminum to restate 2023-2025 financials over Jamalco accounting change

Negative legal/regulatory Written later 4.02

Century Aluminum said its previously issued financial statements for fiscal 2023 and 2024 and several 2024-2025 interim periods should no longer be relied upon. The restatement stems from a change to fully consolidate its Jamalco production assets, after SEC staff disagreed with the company's view that the change was immaterial. The company said the change does not affect net income attributable to Century stockholders, but it expects to report a material weakness in internal controls.

Affected periods include fiscal years ended December 31, 2023 and 2024, and interim periods through September 30, 2025.
2024 gross profit as restated is $172.0 million, down from $185.0 million as previously reported; 2023 gross profit is $87.6 million, down from $91.9 million.
Total assets at December 31, 2024 rise to $2,120.0 million from $1,939.4 million; net income attributable to Century stockholders is unchanged.
The Audit Committee made the conclusion on March 2, 2026, and the company expects a material weakness in internal controls.

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.